Cancer research moves fast. We make it understandable.
In the LIBRETTO-121 trial's primary efficacy population of 25 pediatric and young adult patients with RET-altered solid tumors (including RET-altered thyroid cancer) that had not responded to available therapies, selpercatinib…
Primary source cited
Last reviewed
In a small, phase 1, first-in-human trial, a personalized cancer vaccine built from each patient's own tumor mutations was given after surgery to patients with high-risk kidney cancer. All 9…
Primary source cited
Last reviewed
FAST-02 is a single-arm feasibility trial testing proton FLASH radiotherapy -- an experimental technique that delivers a full course of radiation in under 1 second, more than 100 times faster…
Primary source cited
Last reviewed
In two separate, randomized, double-blind, phase 3 trials (SPOTLIGHT and GLOW), adding zolbetuximab to first-line chemotherapy significantly extended both progression-free survival and overall survival, compared with chemotherapy alone, in patients…
Primary source cited
Last reviewed
In the prospective, single-arm, phase 2 ROBOCOLO trial, robotic-assisted surgery for resectable right-sided colon cancer met its primary safety endpoint (postoperative complication rate within 30 days), supporting robotic surgery as…
Primary source cited
Last reviewed
In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with…
Primary source cited
Last reviewed
A population-based analysis of national mortality data in England (2001-2024) found a substantial reduction in cervical cancer mortality among women aged 20-29 associated with high uptake of England's HPV vaccination…
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 innovaTV 301 trial, tisotumab vedotin significantly extended both overall survival (11.5 months versus 9.5 months) and progression-free survival (4.2 months versus 2.9 months), compared…
Primary source cited
Last reviewed
In the randomized, phase 3 ASCENT-07 trial, sacituzumab govitecan did NOT improve progression-free survival compared with standard-of-care chemotherapy as a first chemotherapy option for hormone-receptor-positive, HER2-negative advanced breast cancer --…
Primary source cited
Last reviewed
In the single-arm, phase 2 FIREFLY-1 trial, tovorafenib produced an objective response (tumor shrinkage or resolution) in about 67% of children and young adults with relapsed or refractory, BRAF-altered pediatric…
Primary source cited
Last reviewed